Found: 14
Select item for more details and to access through your institution.
Pharmacodynamic Effects of Zidovudine 600 mg Once/Day versus 300 mg Twice/Day in Therapy-Naïve Patients Infected with Human Immunodeficiency Virus.
- Published in:
- Pharmacotherapy, 2004, v. 24, n. 3, p. 307, doi. 10.1592/phco.24.4.307.33184
- By:
- Publication type:
- Article
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study.
- Published in:
- Journal of Infectious Diseases, 2013, v. 207, n. 5, p. 740
- By:
- Publication type:
- Article
Safety, Pharmacokinetics, and Antiviral Activity of HGSOO4, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in H1V-1—Infected Patients.
- Published in:
- Journal of Infectious Diseases, 2008, v. 197, n. 5, p. 721, doi. 10.1086/527327
- By:
- Publication type:
- Article
T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen.
- Published in:
- Journal of Infectious Diseases, 2005, v. 191, n. 7, p. 1155
- By:
- Publication type:
- Article
İki Ayda Bir Enjektabl Uzun Etkili Cabotegravir + Rilpivirin (CAB + RPV) Tedavi Rejimi: ATLAS-2M Çalışması 152. Hafta Sonuçları.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2022, v. 11, p. 129
- By:
- Publication type:
- Article
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 9, p. 1646, doi. 10.1093/cid/ciad020
- By:
- Publication type:
- Article
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
- Published in:
- BMC Infectious Diseases, 2003, v. 3, n. 1, p. 10
- By:
- Publication type:
- Article
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 9, p. 1, doi. 10.1093/ofid/ofab439
- By:
- Publication type:
- Article
Long-Acting Cabotegravir+Rilpivirine Every 2 Months: ATLAS-2M Week 152 Results.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 276
- By:
- Publication type:
- Article
Long-acting cabotegravir+rilpivirine every 2 months: ATLAS-2M week 152 results.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S310
- By:
- Publication type:
- Article
Cabotegravir + Rilpivirine Every 2 Months Is Noninferior To Monthly: ATLAS-2M Study.
- Published in:
- Infection & Chemotherapy, 2020, v. 52, p. S378
- By:
- Publication type:
- Article
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
- Published in:
- PLoS ONE, 2018, v. 13, n. 1, p. 1, doi. 10.1371/journal.pone.0190487
- By:
- Publication type:
- Article
Joseph Ransdell and the Communicational Process of Philosophy.
- Published in:
- Transactions of the Charles S. Peirce Society, 2013, v. 49, n. 4, p. 457, doi. 10.2979/trancharpeirsoc.49.4.457
- By:
- Publication type:
- Article
Intraspecific variation in thermal acclimation and tolerance between populations of the winter ant, Prenolepis imparis.
- Published in:
- Ecology & Evolution (20457758), 2020, v. 10, n. 11, p. 4749, doi. 10.1002/ece3.6229
- By:
- Publication type:
- Article